Illinoislawyernow iconIllinoislawyernowSep 28, 2026 ~7 min source read

Why Medical Cannabis Won the Rescheduling Fight and What That Means for Valuation

A 2026 Department of Justice order moved licensed medical marijuana into Schedule III while leaving adult-use in Schedule I. The result: identical revenue can produce very different after-tax profits, and buyers must price medical revenue differently from adult-use.

Share this story

Send the public story page.

Useful takeaways from this story.

Treasury/IRS guidance treats the rescheduling as applying to the full taxable year that includes the order date and requires apportionment of expenses for mixed medical/adult-use businesses.

Deal diligence must prove which license drives reported revenue and document accounting that supports any allocation between medical and adult-use activity.

The useful part

So the split is real today, and it could narrow later, which is why any cannabis rescheduling business valuation done this year needs a plan for both outcomes. Our federal cannabis rescheduling 2026 explainer tracks the process, and Cannabis Legalization News covered the hearing as it happened. Section 280E of the tax code only disallows deductions for businesses trafficking in Schedule I or II substances.

How it works

  • April 23, 2026, Treasury and the IRS announced how tax guidance will work after the order.
  • How big the gap is depends on the target's cost structure, so we won't pretend there's a universal multiple.
  • See our Florida MMTC license transfer guide for how those deals close, and the state's Office of Medical Marijuana Use for the program itself.
  • The order covers marijuana "subject to a state medical marijuana license." Pull the licenses, then pull the point-of-sale data showing which sales ran under which authority.
  • Ask how the target plans to do it and whether its accounting system can prove it.

What to take from it

A store that adds medical sales creates a medical revenue stream a buyer can price separately. Those positions become the buyer's problem in a stock or membership-interest deal. In most cannabis rescheduling business valuation work, often yes, because medical activity under a state medical license is now Schedule III and escapes Section 280E, while adult-use activity remains Schedule I.

Example or evidence

  • Medical marijuana under a state license is now Schedule III, so medical activity escapes 280E while adult-use activity does not.
  • For cannabis rescheduling business valuation, that's the whole ballgame: identical gross revenue can now produce very different net income depending on which license it runs through.
  • Rescheduling generally will be treated as applying for a business's full taxable year that includes the order's effective date.
  • It gets an allocation, and allocations are only as good as the books behind them.

Details worth keeping

It lifted one boat, the medical one, and left adult-use tied to the dock. You can read the order on the Federal Register. Everything else, including adult-use marijuana, stayed in Schedule I.

Related coverage

  • Newswire: The federal governments policy contradiction is unavoidable: The federal government is conferring the legitimacy and financial benefits of Schedule III medicine on state-licensed operators while three of...
  • Newswire: "The federal appeals court left the limited Schedule III order in effect while MMJ's challenge proceeds, but the stay denial did not uphold the order's legality or decide the separate DEA proceeding...
  • Newswire: As the D.C. Circuit prepares to decide whether the Justice Department lawfully moved state marijuana into DEA Schedule 3, experts warn that billions in anticipated tax benefits could unravel.
  • Newswire: Leading Cannabis Law Firm Harris Sliwoski attorney says operators should proceed "very carefully" and warns agreements may have to stop immediately if the federal rescheduling order is overturned.
  • Cannabislaw: InDepth | Implications Of Himachal Pradesh Legalising The Controlled Cultivation Of Cannabis What are the implications of the Himachal Pradesh government legalising the controlled cultivation of cannabis in...

More context around this story.

Cannabis Detected in 21% of U.S. Overdose Deaths
Painnewsnetwork iconPainnewsnetworkSep 3, 2026

Cannabis Detected in 21% of U.S. Overdose Deaths

By Pat Anson A new study by the CDC seems likely to revive an old debate about cannabis: Can you overdose on cannabis? The study, published in the CDC’s Morbidity and Mortality Weekly Report ( MMWR ), looked at U.S. overdoses from 2021 to 2025 and found that cannabis was “detected” in 43,880 deaths. That’s over one in

Loading more related stories...

Keep reading in the app

Open the app view to save this story, compare related coverage, and continue from the same source.

Open in app